Guangdong VTR Bio-Tech Co., Ltd.

SZSE:300381 Stock Report

Market Cap: CN¥3.6b

Guangdong VTR Bio-Tech Balance Sheet Health

Financial Health criteria checks 5/6

Guangdong VTR Bio-Tech has a total shareholder equity of CN¥2.7B and total debt of CN¥91.6M, which brings its debt-to-equity ratio to 3.4%. Its total assets and total liabilities are CN¥3.0B and CN¥286.3M respectively.

Key information

3.4%

Debt to equity ratio

CN¥91.61m

Debt

Interest coverage ration/a
CashCN¥899.74m
EquityCN¥2.67b
Total liabilitiesCN¥286.30m
Total assetsCN¥2.96b

Recent financial health updates

No updates

Recent updates

Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Looks Inexpensive But Perhaps Not Attractive Enough

Sep 30
Guangdong VTR Bio-Tech Co., Ltd. (SZSE:300381) Looks Inexpensive But Perhaps Not Attractive Enough

Guangdong VTR Bio-Tech's (SZSE:300381) Soft Earnings Are Actually Better Than They Appear

May 02
Guangdong VTR Bio-Tech's (SZSE:300381) Soft Earnings Are Actually Better Than They Appear

There's No Escaping Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Muted Revenues Despite A 35% Share Price Rise

Apr 30
There's No Escaping Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Muted Revenues Despite A 35% Share Price Rise

Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Mar 08
Guangdong VTR Bio-Tech Co., Ltd.'s (SZSE:300381) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Financial Position Analysis

Short Term Liabilities: 300381's short term assets (CN¥1.4B) exceed its short term liabilities (CN¥235.3M).

Long Term Liabilities: 300381's short term assets (CN¥1.4B) exceed its long term liabilities (CN¥51.0M).


Debt to Equity History and Analysis

Debt Level: 300381 has more cash than its total debt.

Reducing Debt: 300381's debt to equity ratio has reduced from 44.6% to 3.4% over the past 5 years.

Debt Coverage: 300381's debt is well covered by operating cash flow (218.4%).

Interest Coverage: Insufficient data to determine if 300381's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 02:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guangdong VTR Bio-Tech Co., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jia ChenChangjiang Securities Co. LTD.
Xiao Bao LiuEverbright Securities Co. Ltd.
Baoping ZhangFounder Securities Co., Ltd.